



2023 Report

The Iowa Registry for Congenital and Inherited Disorders (IRCID) continues to be a national leader in surveillance of congenital and inherited disorders and serves as a model program for other states. IRCID conducts active surveillance to identify information about congenital and inherited disorders that occur in Iowa and to Iowa residents.

Since 1983, IRCID has collected information for over 62,000 children with various birth defects. This information is used by health care providers and educators to provide treatment and support services, and by researchers to study risk factors for birth defects and evaluate treatments for birth defects.

IRCID also conducts surveillance for muscular dystrophies – Duchenne, Becker, congenital, distal, Emery-Dreifuss, facioscapulohumeral, limb-girdle, myotonic, and oculopharyngeal. In addition, IRCID has collaborated with the Centers for Disease Control and Prevention (CDC) to develop approaches for active surveillance for stillbirths, newborn screening disorders, birth defects that may be related to Zika virus infection, delivery outcomes of pregnant people who tested positive for SARS-CoV-2, and congenital cytomegalovirus infection.

The surveillance and research efforts of IRCID and its partners provide a valuable resource for the state of Iowa. While taking care to preserve the privacy of families affected by these disorders, IRCID provides important information to state policy makers and public health professionals. We are pleased to perform this important work on behalf of the citizens of Iowa.

### **Surveillance for Birth Defects**

In the United States (US), CDC recognizes three surveillance approaches, each rated differently for completeness of ascertainment of pregnancies with a birth defect.

- Vital Record Reporting: Use of birth and fetal death certificates provided by the state’s Department of Health (Rating: Poor)
- Passive Reporting: Use of medical reports submitted by staff from hospitals, clinics, or other facilities (Rating: Fair to Good)
- Active Reporting: Use of trained personnel who systematically review records in hospitals, clinics, or other facilities (Rating: Excellent)

The term “defect” refers to abnormal development related to body structure, body function, and metabolism, or an error in body chemistry. Typically, a defect is present at birth (congenital), but a recognizable defect may be diagnosed during pregnancy (prenatal) or following birth (postnatal).

Approximately 1 in 33 newborns is affected by a major birth defect in the US. Major defects come with personal and monetary costs for families of these children and for society. Nearly 20% of all infant deaths are caused by major defects. Hospitalizations associated with major defects are longer than those for other conditions and account for about \$9 billion annually for infants.

IRCID has traditionally focused on structural birth defects, which involve a body part that is missing or malformed. Examples include heart defects, spina bifida, clubfoot, and cleft lip and palate. Since 2003, IRCID adopted the recommendations of the National Birth Defects Prevention Network (NBDPN) to focus largely on a core set of major birth defects (see Table 1).

**Table 1. Prevalence (per 10,000 live births) for birth defects in Iowa, 2016-2020 deliveries**

<b>Birth Defect</b>	<b>Total</b>	<b>Prevalence</b>
<b>Brain/Spinal Cord</b>		
Anencephalus	53	2.8
Encephalocele	22	1.2
Holoprosencephaly	45	2.4
Spina bifida without anencephalus	82	4.3
<b>Eye</b>		
Anophthalmia/microphthalmia	32	1.7
Congenital cataract	64	3.4
<b>Ear</b>		
Anotia/microtia	60	3.2
<b>Heart</b>		
Aortic valve stenosis	51	2.7
Atrial septal defect	444	23.5
Atrioventricular septal defect	94	5.0
Coarctation of aorta	135	7.1
Common truncus	11	0.6
Double outlet right ventricle	43	2.3
Ebstein anomaly	15	0.8
Hypoplastic left heart syndrome	56	3.0
Interrupted aortic arch	14	0.7
Pulmonary valve atresia and stenosis	176	9.3
Single ventricle	11	0.6
Tetralogy of Fallot	68	3.6
Total anomalous pulmonary venous return	24	1.3
Transposition of great arteries	54	2.9
Tricuspid valve atresia and stenosis	47	2.5
Ventricular septal defect	1000	52.9
<b>Oral/Facial</b>		
Choanal atresia	10	0.5
Cleft lip only	77	4.1
Cleft lip with cleft palate	150	7.9
Cleft palate without cleft lip	130	6.9
<b>Gastrointestinal</b>		
Biliary atresia	8	0.4
Esophageal atresia/tracheoesophageal fistula	47	2.5
Hirschsprung's disease (congenital megacolon)	31	1.6
Pyloric stenosis	314	16.6
Rectal and large intestinal atresia/stenosis	59	3.1
Small intestinal atresia and stenosis	61	3.2
<b>Genital/Urinary</b>		
Bladder exstrophy	5	0.3
Cloacal exstrophy	1	0.1
Congenital posterior urethral valves <sup>†</sup>	24	2.5
Hypospadias <sup>*,†</sup>	586	60.8
Renal agenesis/hypoplasia	134	7.1

**Table 1. (continued from previous page)**

<b>Birth Defect</b>	<b>Total</b>	<b>Prevalence</b>
<b>Muscle/Skeletal</b>		
Clubfoot	358	19.0
Craniosynostosis	104	5.5
Diaphragmatic hernia	57	3.0
Gastroschisis	53	2.8
Limb deficiencies (reduction defects)	104	5.5
Omphalocele	55	2.9
<b>Syndromes/Chromosomes</b>		
Deletion 22q11.2	28	1.5
Down syndrome (Trisomy 21)	290	15.4
Edwards syndrome (Trisomy 18)	71	3.8
Patau syndrome (Trisomy 13)	37	2.0
Turner syndrome <sup>‡</sup>	36	3.9

\*Includes first-, second-, and third-degree hypospadias.

†Prevalence per 10,000 male live births.

‡Prevalence per 10,000 female live births.

### Birth Defect Research

Because the causes of up to 70% of major birth defects that occur are unknown, research is a critical part of any strategy to prevent these defects. In 1996 the US Congress directed CDC to establish regional centers in birth defect research and prevention. The Iowa Center for Birth Defects Research and Prevention (CBDRP) is one of eight centers initially established by CDC to study risk factors for major defects. Interest in fostering collaboration among state birth defect programs also led to the establishment of NBDPN in 1998.

#### ***National Birth Defects Prevention Network (NBDPN)***

IRCID is an active member of NBDPN, a nationwide association of birth defect surveillance programs. NBDPN provides programs with guidelines to organize their work in a consistent manner and with educational materials and informational resources to promote Birth Defects Prevention Month each January. NBDPN also encourages scientific collaboration among surveillance programs.

#### ***International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR)***

IRCID is an active member of the International Clearinghouse for Birth Defects Research and Prevention (ICBDSR), a worldwide association of birth defect surveillance programs. ICBDSR is affiliated with the World Health Organization and collaborates with birth defect surveillance programs worldwide to foster surveillance activities. In 2015, ICBDSR worked with several programs to establish World Birth Defects Day (WBDD) on March 3<sup>rd</sup>. Since then, ICBDSR has actively participated in annual WBDD activities, including an evaluation of the impact of WBDD. Bolded name refers to an Iowa investigator.

Kleven DL, Mai CT, Bermejo-Sánchez E, Groisman B, Walani S, Peck J, Cosentino V, Botto LD, Zezza S, **Romitti PA**, and Mastroiacovo P (2023). Using a health observance event to raise awareness: An assessment of World Birth Defects Day. Birth Defects Res 115:1140–1150.

### ***Iowa Center for Birth Defects Research and Prevention (CBDRP)***

The Iowa CBDRP participated in the National Birth Defects Prevention Study (NBDPS) and currently participates in the Birth Defects Study To Evaluate Pregnancy exposures (BD-STEPS). NBDPS investigated risk factors for over 30 major defects. IRCID identified children with NBDPS-eligible defects and secured permission from mothers to share information with researchers. Mothers with a pregnancy affected by a major defect and those with an unaffected pregnancy were interviewed about their health, diet, and lifestyle during pregnancy. Biological specimens were requested from families to study genetic factors. Nationwide, over 43,000 interviews were completed, and over 25,000 families provided specimens.

NBDPS and BD-STEPS projects conducted by the Iowa CBDRP have the potential to positively impact the lives of Iowans. These projects examined agricultural chemicals, cigarette smoking, alcohol consumption, diet, medications, and compounds in drinking water, along with genetic factors. Projects published in 2023 that used IRCID data are listed below. Bolded names refer to Iowa investigators.

#### **Iowa NBDPS Project Spotlight**

Congenital heart defects (CHDs) are the most common group of major birth defects, yet risk factors that contribute to the development of CHDs are not well known. Researchers analyzed NBDPS data to study whether use of inactivated flu vaccine in early pregnancy was related to having a baby with a CHD. Among NBDPS participants who reported receiving the vaccine in early pregnancy, researchers did not find a relationship between vaccination and CHDs, compared to women who did not receive the vaccine or received the vaccine later in pregnancy. These findings support the use of inactivated flu vaccine during early pregnancy as recommended by the American College of Obstetricians and Gynecologists.

Palmsten K, **Suhl J**, **Conway KM**, Kharbanda EO, **Scholz TD**, Ailes EC, Cragan JD, Nestoridi E, Papadopoulos EA, Kerr SM, Young SG, Olson C, **Romitti PA**; National Birth Defects Prevention Study. (2023) Influenza vaccination during pregnancy and risk of selected major structural congenital heart defects, National Birth Defects Prevention Study 2006-2011. [Birth Defects Res](#) 115:88-95.

Blue EE, White JJ, Dush MK, Gordon WW, Wyatt BH, White P, Marvin CT, Helle E, Ojala T, Priest JR, Jenkins MM, Almlı LM, Reefhuis J, Pangilinan F, Brody LC, McBride KL, Garg V, Shaw GM, **Romitti PA**, Nembhard WN, Browne ML, Werler MM, Kay DM; National Birth Defects Prevention Study; University of Washington Center for Mendelian Genomics; Mital S, Chong JX, Nascone-Yoder NM, Bamshad MJ. (2023) Rare variants in CAPN2 increase risk for isolated hypoplastic left heart syndrome. [HGG Adv](#) 4:100232.

Fisher SC, Howley MM, Tran EL, Ailes EC, Papadopoulos EA, Nembhard WN, Browne ML, and National Birth Defects Prevention Study and the Birth Defects Study to Evaluate Pregnancy Exposures (2023). Maternal cyclobenzaprine exposure and risk of birth defects in the National Birth Defects Prevention Study (1997-2011) and Birth Defects Study to Evaluate Pregnancy exposures (2014-2018). [Pharmacoepidemiology and drug safety](#), 32(8), 855–862.

Howley MM, Fisher SC, Van Zutphen AR, Papadopoulos EA, Patel J, Lin AE, Browne ML; National Birth Defects Prevention Study. (2023) Maternal exposure to heparin products and risk of birth defects in the National Birth Defects Prevention Study. [Birth Defects Res](#) 115:133-144.

Huang M, Lyu C, Liu N, Nembhard WN, Witte JS, Hobbs CA, Li M, and National Birth Defects Prevention Study (2023). A gene-based association test of interactions for maternal-fetal genotypes identifies genes associated with nonsyndromic congenital heart defects. [Genet Epidemiol](#) 47:475–495.

Marchincin SL, Howley MM, Van Zutphen AR, Fisher SC, Nestoridi E, Tinker SC, Browne ML; National Birth Defects Prevention Study. (2023) Risk of birth defects by pregestational type 1 or type 2 diabetes: National Birth Defects Prevention Study, 1997–2011. Birth Defects Res 115:56-66.

Pruitt Evans S, Ailes EC, Kramer MR, Reefhuis J, Insaf TZ, Yazdy MM, Carmichael SL, **Romitti PA**, Feldkamp ML, Neo DT, Nembhard WN, Shaw GM, Palmi E, Gilboa SM, National Birth Defects Prevention Study. (2023) Neighborhood deprivation and neural tube defects. Epidemiol 34:774-785.

Schrager NL, Parker SE, Werler MM, for the National Birth Defects Prevention Study. (2023) The association of nausea and vomiting of pregnancy, its treatments, and select birth defects: Findings from the National Birth Defect Prevention Study. Birth Defects Res 115:275-289.

Siegel MR, Rocheleau CM, Hollerbach BS, Omari A, Jahnke SA, Almli LM, Olshan AF, National Birth Defects Prevention Study. (2023) Birth defects associated with paternal firefighting in the National Birth Defects Prevention Study. Am J Ind Med 66:30-40.

Sok P, Sabo A, Almli LM, Jenkins MM, Nembhard WN, Agopian AJ, Bamshad MJ, Blue EE, Brody LC, Brown AL, Browne ML, Canfield MA, Carmichael SL, Chong JX, Dugan-Perez S, Feldkamp ML, Finnell RH, Gibbs RA, Kay DM, Lei Y, Meng Q, Moore CA, Mullikin JC, Muzny D, Olshan AF, Pangilinan F, Reefhuis J, **Romitti PA**, Schraw JM, Shaw GM, Werler MM, Harpavat S, Lupo PJ, University of Washington Center for Mendelian Genomics, NISC Comparative Sequencing Program, the National Birth Defects Prevention Study. (2023) Exome-wide assessment of isolated biliary atresia: using child-parent trios and a case-control design to identify novel rare variants. Am J Med Genet A 191:1546-1556.

**Suhl J, Conway KM, Rhoads A**, Langlois PH, Feldkamp M, Michalski A, Oleson J, Sidhu A, Scholz T, Kancherla V, Obrycki J, Mazumdar M, **Romitti PA**, and National Birth Defects Prevention Study. (2023) Pre-pregnancy exposure to arsenic in diet and congenital heart defects. Birth Defects Res 115:79-87.

Weber KA, Yang W, Carmichael SL, Collins RT 2nd, Luben TJ, Desrosiers T, Insaf T, Le M, Evans S, **Romitti PA**, Yazdy MM, Nembhard WN, Shaw GM; National Birth Defects Prevention Study. (2023) Assessing associations between residential proximity to greenspace and birth defects in the National Birth Defects Prevention Study. Environ Res 216:114760.

Williford E, Howley M, Fisher S, **Caspers Conway K, Romitti PA**, Reeder M, Olshan A, Reefhuis J, Browne M, National Birth Defects Prevention Study. (2023) Maternal dietary caffeine consumption and risk of birth defects in the National Birth Defects Prevention Study, 1997-2011. Birth Defects Res 115:921-932.

Van Buren KW, Rocheleau CM, Chen IC, Desrosiers TA, Sanderson W, Politis M, Ailes E, and National Birth Defects Prevention Study. (2023) Maternal occupational exposure to selected organic and chlorinated solvents and delivery of small-for-gestational age or preterm infants. Am J Ind Med 66:842–853.

Webber DM, Li M, MacLeod SL, Tang X, Levy JW, Karim MA, Erickson SW, Hobbs CA, and The National Birth Defects Prevention Study. (2023) Gene-folic acid interactions and risk of conotruncal heart defects: Results from the National Birth Defects Prevention Study. Genes 14:180.

## Surveillance for Muscular Dystrophy

Muscular dystrophies (MDs) are a group of genetic progressive muscle diseases affecting an estimated 33 per 100,000 individuals and are characterized by worsening muscle weakness. Historically, types of MDs were diagnosed by known changes in muscle and clinical presentation; presently, diagnosis is determined largely by genetic analysis. Ages at symptom onset of MDs can range from birth through late adulthood. In children, Duchenne is the most common childhood MD, followed by congenital MDs. In adults, myotonic dystrophy is the most common MD, followed by facioscapulohumeral MD.

### ***Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet)***

MD STARnet is a surveillance program currently active in seven states (Florida, Iowa, New York, North Carolina, South Carolina, Utah, Virginia) and funded by CDC. The goals of MD STARnet are to define and describe the MD population in the US, define and describe healthcare needs and outcomes for individuals living with MD, and collect information to guide MD care, treatment, and policy. On behalf of MD STARnet, IRCID conducts surveillance of Iowans who have been diagnosed with one of eight MDs and meet residence, diagnostic, and treatment period criteria (Table 2). Our surveillance consists of identification and ongoing medical chart review to identify individuals with at least one eligible MD diagnostic code (International Classification of Disease [ICD], ICD-9, ICD-10). The table below summarizes the number of Iowa individuals identified for MD STARnet, followed by MD STARnet projects published in 2023. Bolded names refer to Iowa investigators.

**Table 2. Number of individuals identified with a muscular dystrophy among Iowa residents**

Phase of Surveillance/Muscular Dystrophy	Total
<b>Phase I*</b>	
Duchenne or Becker	140
<b>Phase II†</b>	
Becker	52
Congenital	24
Distal	5
Duchenne	105
Emery-Dreifuss	12
Facioscapulohumeral	81
Limb-Girdle	66
Myotonic	253
Oculopharyngeal	17
<b>Phases III and IV</b>	
Becker‡	30
Congenital^	35
Distal^	8
Duchenne‡	79
Emery-Dreifuss^	20
Facioscapulohumeral^	131
Limb-Girdle^	142
Myotonic^	419
Oculopharyngeal§	37

\* Resident individual with MD diagnosis born on or after January 1, 1982 through December 31, 2011 who lived in Arizona, Colorado, Georgia, Hawaii, Iowa, or western New York.

† Resident individual with MD diagnosis and health encounter from January 1, 2007 through December 31, 2011 who lived in Arizona, Colorado, Iowa, or western New York.

‡ Phase III: Resident individual with MD diagnosis born on or after January 1, 2000 and health encounter from January 1, 2000 through December 31, 2015 who lived in Colorado, Iowa, western New York, North Carolina, South Carolina, or Utah.

Phase IV: Resident individual with MD diagnosis born on or after January 1, 2000 and health encounter from January 1, 2000 through December 31, 2020 who lived in Florida, Iowa, western New York, North Carolina, South Carolina, Utah, or Virginia.

^ Phase III: Resident individual with MD diagnosis since January 1, 2008 and health encounter from January 1, 2008 through December 31, 2016 who lived in Colorado, Iowa, western New York, North Carolina, South Carolina, or Utah.

Phase IV: Resident individual with MD diagnosis and health encounter from January 1, 2008 through December 31, 2020 who lived in Florida, Iowa, western New York, North Carolina, South Carolina, Utah, or Virginia.

§ Phase III: Resident individual with MD diagnosis and health encounter from January 1, 2006 through December 31, 2016 who lived in Colorado, Iowa, western New York, North Carolina, South Carolina, or Utah.

### **Iowa MD STARnet Project Spotlight**

Epidemiological support for prophylactic treatment of left ventricular dysfunction in Duchenne muscular dystrophy is limited. We used retrospective, population-based surveillance data from the Muscular Dystrophy Surveillance, Tracking and Research Network to evaluate whether prophylaxis delays onset of left ventricular dysfunction. We found significant delays of left ventricular dysfunction among people treated with cardiac medication at least one year before an abnormal echocardiogram. Combined treatment with corticosteroids and prophylactic cardiac medications showed the strongest protection against left ventricular dysfunction. Proactive cardiac treatment and monitoring are critical aspects of managing Duchenne muscular dystrophy. Consistent with clinical care guidelines, this study supports clinical benefit from cardiac medications initiated prior to documented LVD and suggests further benefit when combined with corticosteroids.

**Conway KM**, Thomas S, Ciafaloni E, Khan RS, Mann JR, **Romitti PA**, **Mathews KD**, and the Muscular Dystrophy Surveillance, Tracking, and Research Network (2023). Prophylactic use of cardiac medications for delay of left ventricular dysfunction in Duchenne muscular dystrophy. [Birth Defects Res.](#) 116:e2260.

Kang PB, Jorand-Fletcher M, Zhang W, McDermott SW, Berry R, Chambers C, Wong KN, Mohamed Y, Thomas S, Venkatesh YS, Westfield C, Whitehead N, Johnson NE; Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). (2023) Genetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network. [Neurol Genet](#) 9:e200113.

Mann JR, Zhang Y, McDermott S, Wang Y, Cai B, **Conway KM**, Paramsothy P, Royer J, Venkatesh S, Howard JF Jr, Ciafaloni E, and MD STARnet. (2023) Racial and ethnic differences in timing of diagnosis and clinical services received in Duchenne muscular dystrophy. [Neuroepidemiology](#) 57:90–99.

Whitehead N, Erickson SW, Cai B, McDermott S, Peay H, Howard JF, Ouyang L, and Muscular Dystrophy Surveillance, Tracking and Research Network. (2023) Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States. [Orphanet J Rare Dis](#) 18:65.



## Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET)

SET-NET aims to understand effects of emerging and reemerging threats on pregnant people and their infants. To accomplish this, surveillance programs participating in SET-NET work to detect the effects of these threats by collecting data from pregnancy through childhood and use these data to inform clinical decision-making and public health action. IRCID continues to participate in national projects led by CDC.

### ***Microcephaly and Other Birth Defects Related to Zika Virus Exposure***

Congenital microcephaly (MC) is a serious birth defect characterized by an abnormally small head size in affected infants compared to infants of the same sex and gestational age. A dramatic increase in MC in infants in Brazil was linked to pregnant people infected with Zika virus. Zika virus exposure poses a serious risk to an unborn fetus; thus, more timely surveillance is needed for monitoring MC and other birth defects that may be related to Zika virus exposure among pregnant people. To conduct this surveillance, IRCID created a rapid response team comprised of experienced surveillance professionals.

### ***Outcomes Related to SARS-CoV-2 Infection among Pregnant People***

In 2021, IRCID joined the CDC SET-NET to study outcomes for pregnant people infected by the SARS-CoV-2 virus and their offspring. The initial focus of this work is to conduct statewide surveillance of birth outcomes among pregnant people with a laboratory-confirmed SARS-CoV-2 infection in 2020. To date, IRCID has identified more than 3,000 deliveries among pregnant people in Iowa with SARS-CoV-2 infection during pregnancy.

### ***Outcomes Related to Cytomegalovirus Infection among Pregnant People***

In 2023, IRCID expanded its surveillance of emerging threats by studying outcomes related to cytomegalovirus infection (CMV) among pregnant people. To conduct this surveillance the Iowa Department of Health and Human Services issued a reporting order making CMV a reportable infection in Iowa beginning in September 2023. IRCID uses data on CMV infection to identify infants diagnosed with congenital CMV in the first weeks of life.

## Iowa Registry for Congenital and Inherited Disorders Personnel

### **Director**

Paul A Romitti, PhD

### **Clinical Directors for Birth Defects**

Thomas Scholz, MD

Alpa Sidhu MD, PhD

### **Clinical Director for Neuromuscular Disorders**

Katherine Mathews, MD

### **Program Director**

Julie Stutler, MPH

### **Surveillance Manager**

Carrie Fall, BAS, RHIT

### **Data Manager**

Florence Foo, MA

### **Surveillance Field Staff**

Patricia Ganzer Holland

Tahereh Neyaz, MPH

### **Executive Officer and State Genetics Coordinator,**

### **Center for Congenital and Inherited Disorders, Iowa Department of Public Health**

Kimberly Piper, RNC, BS, CPH, CPHG



**IOWA**

College of  
Public Health

**IOWA**<sup>TM</sup>

Health and  
Human Services

*The Iowa Registry for Congenital and Inherited Disorders is a collaborative program of the University of Iowa College of Public Health and Iowa Department of Health and Human Services.*

## Acknowledgements

We gratefully acknowledge the assistance and collaboration of the following Iowa agencies and organizations:

The University of Iowa

- Carver College of Medicine
- College of Public Health
- Governmental Relations Office

Center for Congenital and Inherited Disorders Advisory Committee

Iowa Child Health Specialty Clinics

Iowa Department of Health and Human Services

Iowa Regional Genetic Consultation Service

Iowa Board of Regents

State Hygienic Laboratory of Iowa

### **IRCID surveillance activities are funded by:**

State of Iowa through a special appropriation to the Board of Regents  
State of Iowa through a fee on issuance of birth certificates

Centers for Disease Control and Prevention

### **IRCID research activities are funded by:**

Centers for Disease Control and Prevention

National Institutes of Health

### **IRCID educational activities are funded by:**

Centers for Disease Control and Prevention

Development and publication of this report was supported by funds appropriated by the Iowa General Assembly to the State Board of Regents.

### **Contact Information**

Iowa Registry for Congenital and Inherited Disorders

UI Research Park

134 HLI

Iowa City, IA 52242-5000

Phone: 319-335-4107

Toll-free: 866-274-4237

Fax: 319-335-4030

E-mail: [ircid@uiowa.edu](mailto:ircid@uiowa.edu)

Website: <https://ircid.public-health.uiowa.edu/>